JAK inhibitors in COVID-19: the need for vigilance regarding increased inherent thrombotic risk

Puja Mehta, Coziana Ciurtin, Marie Scully, Marcel Levi, Rachel C. Chambers

Source: Eur Respir J, 56 (3) 2001919; 10.1183/13993003.01919-2020
Journal Issue: September
Disease area: Pulmonary vascular diseases, Respiratory critical care

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Puja Mehta, Coziana Ciurtin, Marie Scully, Marcel Levi, Rachel C. Chambers. JAK inhibitors in COVID-19: the need for vigilance regarding increased inherent thrombotic risk. Eur Respir J, 56 (3) 2001919; 10.1183/13993003.01919-2020

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.

Related content which might interest you:
The cardiovascular effects of xanthines and selective PDE inhibitors: a risk–benefit analysis
Source: Eur Respir Monogr 2020; 88: 279-286
Year: 2020

Rho kinase inhibitors for pulmonary hypertension: waiting for clinical evidence
Source: Eur Respir J 2010; 36: 709-711
Year: 2010

JAK inhibitors overcome corticosteroid insensitivity in COPD
Source: Annual Congress 2011 - COPD: clinical studies and animal cell models
Year: 2011

Community acquired pneumonia: an increased risk for subsequent cardiovascular events?
Source: Virtual Congress 2020 – Cardiovascular and pulmonary complications of respiratory infections
Year: 2020

TB failures, risk factors and therapeutical results
Source: Eur Respir J 2003; 22: Suppl. 45, 523s
Year: 2003

Pulmonary arterial hypertension associated with protein kinase inhibitors: a pharmacovigilance–pharmacodynamic study
Source: Eur Respir J, 53 (5) 1802472; 10.1183/13993003.02472-2018
Year: 2019

Increased reporting of fatal pneumonitis associated with immune checkpoint inhibitors: a WHO pharmacovigilance database analysis
Source: Eur Respir J, 55 (6) 2000038; 10.1183/13993003.00038-2020
Year: 2020

Avoiding confusion in COPD: from risk factors to phenotypes to measures of disease characterisation
Source: Eur Respir J 2011; 38: 749-751
Year: 2011

RV568, a narrow-spectrum kinase inhibitor with p38 MAPK-a and -? selectivity, suppresses COPD inflammation
Source: Eur Respir J, 50 (4) 1700188; 10.1183/13993003.00188-2017
Year: 2017

Pulmonary complications of tyrosine kinase inhibitors in myeloproliferative disorders
Source: Eur Respir J, 56 (4) 2002653; 10.1183/13993003.02653-2020
Year: 2020

Known and emerging risk factors for asthma development: is prevention possible?
Source: International Congress 2015 – Asthma: emerging risk factors and current management of the patient
Year: 2015

PI3K inhibitor add-on strategy improve glucocorticoid insensitivity in severe asthma
Source: Virtual Congress 2020 – Asthma science: novel targets and mechanisms
Year: 2020

Prolonged anticoagulation in VTE with direct oral anticoagulants: towards an individual analysis of net clinical benefit?
Source: Eur Respir J 2016; 48: 1268-1270
Year: 2016

Evaluation of the incidence of rare diseases: difficulties and uncertainties, the example of chronic thromboembolic pulmonary hypertension
Source: Eur Respir J , 49 (2) 1602522; DOI: 10.1183/13993003.02522-2016
Year: 2017

The frequency of chronic thromboembolic pulmonary hypertension and associated risk factors
Source: Annual Congress 2011 - Prediction of pulmonary thromboembolism
Year: 2011

Management of acute pulmonary thrombo-embolic disease (PTE) linking mortality risk to treatment strategies
Source: Annual Congress 2009 - Pulmonary circulation II
Year: 2009

The selective Rho kinase inhibitor trans-6-((4-aminocyclohexyl)amino)-5-fluoro-2-methoxynicotinamide ameliorates experimental pulmonary hypertension
Source: International Congress 2017 – Experimental PH
Year: 2017

Incidence and specific risk factors of falling in pulmonary rehabilitation
Source: Annual Congress 2010 - Pulmonary rehabilitation: understanding and developing the intervention
Year: 2010

Targeting EGFR signalling in chronic lung disease: therapeutic challenges and opportunities
Source: Eur Respir J 2014; 44: 513-522
Year: 2014

An innovative risk score for prediction of asthma related adverse outcome
Source: Annual Congress 2009 - Quality of treatment in primary respiratory care
Year: 2009